Skip to main content

Table 6 Univariate analyses of clinical and tumor factors associated with EpCAM/CD133 in 39 HCC patients

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

Variables

 

Epcam

  

CD133

 
 

P value

OR

95% CI

P value

OR

95% CI

Age (≥55/<55)

0.719

1.27

0.34-4.73

0.726

1.25

0.39-4.36

Gender (Female/male)

0.656

1.50

0.25-9.00

0.101

4.17

0.76-23.07

AFP (ng/ml) (≥20/<20)

0.066

3.75

0.92-15.34

1.000

1.00

0.29-3.48

Tumor number (≥2/1)

0.206

2.37

0.62-9.03

0.162

0.43

0.13-1.41

Tumor size,cm (≥3/<3)

0.547

0.67

0.18-2.49

0.292

1.89

0.58-10.93

TNM stage

0.206

2.37

0.62-9.25

0.068

0.30

0.08-1.10

Differentiation

0.033

5.36

1.15-25.06

0.154

2.4

0.72-7.97

(well/moderate/poor)

      

TACE treatment/not

0.012

6.43

1.57-27.45

0.070

3.47

0.90-13.31

  1. AFP,α-fetoprotein; TACE, Transarterial chemoembolization.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us